Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PYC Therapeutics Limited ( (AU:PYC) ) has provided an update.
PYC Therapeutics announced progress in its Phelan-McDermid Syndrome (PMS) program, presenting data at the PMS Global Congress in Barcelona. The data shows that their drug candidate, PYC-002, restores missing gene expression and rescues functional deficits in neurons, addressing the underlying cause of PMS. This advancement is significant as there are currently no approved treatments for PMS, and the program is expected to enter clinical trials in about 12 months, marking the company’s fourth first-in-class drug candidate with disease-modifying potential.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases with no available options. The company has three clinical-stage drug development programs and a pre-clinical stage program targeting Phelan-McDermid Syndrome (PMS), a severe neurodevelopmental disorder affecting 1 in every 10,000 children.
Average Trading Volume: 443,085
Technical Sentiment Signal: Buy
Current Market Cap: A$749.5M
Learn more about PYC stock on TipRanks’ Stock Analysis page.